Onkologie. 2023:17(2):90-94 | DOI: 10.36290/xon.2023.019

The role of radiotherapy in the treatment of pancreatic cancer

Renata Soumarová, Marián Liberko
Onkologická klinika FNKV, Praha
3. lékařská fakulta Univerzity Karlovy v Praze

Surgery remains the most important modality in the treatment of resectable pancreatic cancer, but only 10-15% of patients are suitable candidates. Despite the still high rate of local recurrence after radical surgery, adjuvant radiotherapy has now been replaced by chemotherapy, which has been shown to have better outcomes in randomized trials. Systemic therapy is also preferred in the neoadjuvant indication, but further studies investigating the position of radiotherapy in this group of patients are needed. Radiotherapy has a place in unresectable disease, where in combination with systemic therapy it affects local disease control and overall survival. New radiotherapy techniques including hypofractionated ablative and stereotactic radiotherapy are preferred. In metastatic disease, radiation to metastases may also be considered with palliative intent or to delay disease progression and improve survival. The use of new technologies for imaging and radiotherapy planning continues to evolve, but the combination of radiotherapy with more effective systemic therapy is also being used more.

Keywords: resectable pancreatic cancer, unresectable pancreatic cancer, locally advanced pancreatic cancer, adjuvant radiotherapy, stereotactic radiotherapy, hypofractionated radiotherapy.

Accepted: April 26, 2023; Published: April 27, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soumarová R, Liberko M. The role of radiotherapy in the treatment of pancreatic cancer. Onkologie. 2023;17(2):90-94. doi: 10.36290/xon.2023.019.
Download citation

References

  1. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006-2010. Go to original source... Go to PubMed...
  2. Klinkenbijl J, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg. 1999;230:776-782. Go to original source... Go to PubMed...
  3. Neoptolemos JP, Stocken DD, Friess H, et al. Role of Radiation Therapy in Pancreas Cancer randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210. Go to original source... Go to PubMed...
  4. Regine W, Winter KA, Abrams R, et al. A phase III Intergroup trial (RTOG 97-04) of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys.20006;66:S23-S24.
  5. Griffin J, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 1990;66:56-61. Go to original source...
  6. Safran H, Winter K, Abrams RA, et al. Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma. J Clin Oncol. 2017;35:4007. Go to original source...
  7. Ren F, Xu YC, Wang HX, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, for resectable advanced pancreatic adenocarcinoma: continue or stop? Pancreatology. 2012;12(2):162-169. Go to original source... Go to PubMed...
  8. Liao WC, Chien KL, Lin YL, et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol 2013;14(11):1095-1103. Go to original source... Go to PubMed...
  9. Luo Y. The role of radiotherapy for pancreatic malignancies: a population‑based analysis of the SEER database. Clinical and Translational Oncology. 2022;24:76-83. Go to original source... Go to PubMed...
  10. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011-1024. Go to original source... Go to PubMed...
  11. Ghaneh P, Kleeff J, Halloran ChM, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg. 2019;269(3):520-529. Go to original source... Go to PubMed...
  12. van Dam JL, Janssen QP, Besselink MG, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. European Journal of Cancer. 2022;140-149. Go to original source... Go to PubMed...
  13. Versteijne E, Suker M, Groothuis K, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. JCO. 2020.
  14. Suker M, Nuyttens JJ, Groot Koerkamp B, et al. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. J Surg Oncol. 2018;118:1021-1026. Go to original source... Go to PubMed...
  15. Neoadjuvant FOLFIRINOX versus neoadjuvant chemoradiotherapy and adjuvant chemotherapy for (borderline) resectable pancreatic carcinoma: the PREOPANC-2 study. Available from: https://www. trialregister.nl/trial/7094.
  16. Katz M, Shi Q, Meyers A, et al. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the PancreasThe A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022;8(9):1263-1270. Go to original source... Go to PubMed...
  17. Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022.
  18. Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic Cancer controlled after 4 months of gemcitabine with or without Erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844-1853. Go to original source... Go to PubMed...
  19. Krishnan S, Chadha AS, Suh Y, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic Cancer patients receiving induction chemotherapy and consolidative Chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94(4):755-765. Go to original source... Go to PubMed...
  20. Rudra S, Jiang N, Rosenberg A, et al. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Med. 2019;8(5):2123-2132. Go to original source... Go to PubMed...
  21. Reyngold M, Parikh P, Crane ChH. Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results. Radiat Oncol. 2019;6:4(1):95. Go to original source... Go to PubMed...
  22. Petrelli F, Comito T, Ghidini A, et al. Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials. Int J Radiat Oncol Biol Phys. 2017;97(2):313-322. Go to original source... Go to PubMed...
  23. de Geus SWL, Eskander MF, Kasumova GG, et al. Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review. Cancer. 2017;123(21):4158-4167. Go to original source... Go to PubMed...
  24. Iacobuzio-Donahue CA, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27(11): 1806-1813. Go to original source... Go to PubMed...
  25. Oar A, Lee M, Le H, et al. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer. 2021;21:936. Go to original source... Go to PubMed...
  26. Henke L, Kashani R, Robinson C, et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol. 2018;126:519-526. Go to original source... Go to PubMed...
  27. Scorsetti M, Comito T, Franceschini D, et al. Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. Br J Radiol. 2020; 93:20190627. Go to original source... Go to PubMed...
  28. Lee G, Kim DW, Oladeru OT, et al. Liver metastasis-directed ablative radiotherapy in pancreatic cancer offers prolonged time off systemic therapy: Data from a multi-institutional retrospective study. Pancreas. 2021;50:736-743. Go to original source... Go to PubMed...
  29. Bernstein MB, Krishnan S, Hodge JW, et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016;13(8):516-524. Go to original source... Go to PubMed...
  30. Venkatesulu BP, Cheng-En Hsieh, Sanders KL, et al. Recent advances in radiation therapy of pancreatic cancer. F1000Research 2018, 7(F1000 Faculty Rev):1931 Last updated:14 DEC 2018.
  31. Palta M, Godfrey D, Goodman KA, et al. ASTRO Guideline Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Practical Radiation Oncology. 2019;9:322-332. Go to original source... Go to PubMed...
  32. Nelson B, Barrord M, Wang K, et al. Relationship of dose to vascular target volumes and local failure in pancreatic cancer patients undergoing neoadjuvant chemoradiation. Front Oncol. 2022;12:906484. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.